Request Deal Involvement
Ardian-backed Neopharmed Gentili to acquire the European Orladeyo berotralstat business from BioCryst Pharmaceuticals for $264m.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
pr advisors
H/Advisors Abernathy
financial advisors
PricewaterhouseCoopers
tax advisors
PricewaterhouseCoopers
commercial advisors
ValueVector
pr advisors
Value Relations
pr advisors
Landi Consulting
commercial advisors
ZS Associates
financial advisors
Centerview Partners
legal advisors
White & Case
legal advisors
Skadden Arps Slate Meagher & Flom
financial advisors
Bank of America
financial advisors
TD Cowen
or
Principals
bidder
ARDIAN SAS (FORMERLY AXA PRIVATE EQUITY)
target
BIOCRYST PHARMACEUTICALS (EUROPEAN ORLADEYO BEROTRALSTAT BUSINESS)
bidder
NEOPHARMED GENTILI
vendor
BIOCRYST PHARMACEUTICALS INC
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite